Schuldbeladen nehme ich mein Los als "Seuchenträgerbefürworter" an :DDr.Shrimp schrieb:Genau so könnte es kommen, ja. :D
Ich bin ja gar nicht ausdrücklich für eine Impfpflicht.Ilvi schrieb:Ich habe mit gelesen, dennoch bin ich so oft du auch die Wichtigkeit dessen für dich erkennst, gegen eine Impfpflicht!!!
Einfach weil ich selbst entscheiden möchte was meinem Körper zugeführt wird und was nicht.
Ich glaube nicht, dass da oben jemand ist, der dich was fragen könnte.
Unexplained cases of sudden infant death shortly after hexavalent vaccination.” Zinka B, Rauch E, Buettner A, Rueff F, Penning R. – Vaccine. 2005 May 18
Vaccinations are considered to be the most effective and safe method preventing infectious diseases. Although hexavalent vaccines like Hexavac((R)) and Infanrix Hexa((R)) are assumed to be well tolerated and safe regarding the rate of immunity [Liese JG, Stojanov S, Berut F, Minini P, Harzer E, Jow S, et al. Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP-T-HBs) administered at 2, 4, 6 and 12-14 months of age. Vaccine 2002;20:448-54; Mallet E, Fabre P, Pines E, Salomon H, Staub T, Schodel F, et al. Immunogenicity and safety of a new liquid hexavalent combines vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 2000;19:1119-27], it was noticed that several cases of death occurred shortly after the vaccination. We report six cases of sudden infant death that occurred within 48h after hexavalent vaccination. At post-mortal examination, those cases showed unusual findings, especially in the brain and in laboratory tests. Crude calculations of local epidemiology are compatible with an association between hexavalent vaccination and unusual cases of sudden infant death. If confirmed in systematic studies, our findings would have potentially serious clinical implications.
Neonatal Deaths After Hepatitis B Vaccine – The Vaccine Adverse Event Reporting System, 1991-1998 – Arch Pediatr Adolesc Med. 1999;153:1279-1282
Results: Of 1771 neonatal reports, there were 18 deaths in 8 boys and 9 girls (1 patient unclassified). The mean age at vaccination for these 18 cases was 12 days(range, 1-27 days); median time from vaccination to onset of symptoms was 2 days (range, 0-20 days); and median time from symptoms to death was 0 days (range, 0-15 days). The mean birth weight of the neonates (n = 15) was 3034 g (range, 1828-4678 g). The causes of death for the 17 autopsied cases were sudden infant death syndrome for 12, infection for 3, and 1 case each of intracerebral hemorrhage, accidental suffocation, and congenital heart disease. Conclusion: Few neonatal deaths following HepB vaccination have been reported, despite the use of at least 86 million doses of pediatric vaccine given in the United States since 1991. While the limitations of passive surveillance systems do not permit definitive inference, these data suggest that HepB immunization is not causing a clear increase in neonatal deaths.
Recombinant hepatitis B vaccine and the risk of multiple sclerosis
NEUROLOGY 2004;63:838-842
A prospective study
Miguel A. Hernán, MD, DrPH, Susan S. Jick, DSc, Michael J. Olek, DO and Hershel Jick, MD
From the Department of Epidemiology (Dr. Hernán), Harvard School of Public Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. Susan S. Jick and Hershel Jick), Boston University, Lexington, MA; and Department of Neurology (Dr. Olek), College of Medicine, University of California, Irvine.
Background: A potential link between the recombinant hepatitisB vaccine and an increased risk of multiple sclerosis (MS) hasbeen evaluated in several studies, but some of them have substantialmethodologic limitations.
Methods: The authors conducted a nested case-control study withinthe General Practice Research Database (GPRD) in the UnitedKingdom. The authors identified patients who had a first MSdiagnosis recorded in the GPRD between January 1993 and December2000. Cases were patients with a diagnosis of MS confirmed throughexamination of medical records, and with at least 3 years ofcontinuous recording in the GPRD before their date of firstsymptoms (index date). Up to 10 controls per case were randomlyselected, matched on age, sex, practice, and date of joiningthe practice. Information on receipt of immunizations was obtainedfrom the computer records.
Results: The analyses include 163 cases of MS and 1,604 controls.The OR of MS for vaccination within 3 years before the indexdate compared to no vaccination was 3.1 (95% CI 1.5, 6.3). Noincreased risk of MS was associated with tetanus and influenzavaccinations.
Conclusions: These findings are consistent with the hypothesisthat immunization with the recombinant hepatitis B vaccine isassociated with an increased risk of MS, and challenge the ideathat the relation between hepatitis B vaccination and risk ofMS is well understood.
Received March 31, 2004. Accepted in final form May 8, 2004.
“Multiple sclerosis and hepatitis B vaccination: Adding the credibility of molecular biology to an unusual level of clinical and epidemiological evidence” Comenge Y; Girard M (Med Hypotheses, doi 10.1016/j.mehy.2005.08.012)
“Autoimmune hazards of hepatitis B vaccine” Girard M (Autoimmun Rev 2005; 4:96-100) (Text available in electronic form on request.)
______________________________________
Low Prevalence in The UK of Hepatitis B and Infections acquired abroad
The prevalence of hepatitis B infection in adults in England and Wales – Epidemiology and Infection (1999), 122:133-138 Cambridge University Press
Cost effectiveness analyses of alternative hepatitis B vaccination programmes in England and Wales require a robust estimate of the lifetime risk of carriage. To this end, we report the prevalence of infection in 3781 anonymized individuals aged 15–44 years whose sera were submitted in 1996 to 16 microbiology laboratories in England and Wales. One hundred and forty-six individuals (3·9%) were confirmed as anti HBc positive, including 14 chronic carriers (0·37%). The prevalence of infection and carriage was higher in samples collected in London and increased with age. No increased risk of infection was seen in sera from genito-urinary (GUM) clinics. Only 15 sera positive for hepatitis B were also positive for hepatitis C. Our results confirm the low prevalence of hepatitis B in England and Wales, are consistent with previous estimates of carriage and suggest that many infections were acquired while resident outside the UK. Future prevalence studies should determine the country of birth and other risk factors for each individual in order to confirm these findings. (Accepted September 14 1998)
genau herausgezogen?derpioneer schrieb:schau dir die zahlen ganz genau an, die darin vorkommen. und berechne mal alleine die sterberate bei babys durch hepatitis-impfungen. von späteren autoimmunerkrankungen oder anderen erkrankungen, die in 10, 20 jahren eintreten werden gar nicht zu reden.
Hep B:
aber es gibt Belege, dass es mit multipler Sklerose assoziiert ist.
Nein, das denke ich, tust Du nicht.
ich denke ich weiß wovon ich spreche.
Es ist sogar recht gut gesichert, dass sie das nicht sind. Gerade wegen der mangelnden Wirksamkeit wurde der Impfstoff nicht mehr weiter verwendet.
@Dr.Shrimp ist zwar manchmal ein komischer Typ, aber ich bezweifel' stark, dass er anthropophag lebt.
Und warum hast du dann keine Ahnung von Impfstoffen, Immunologie und Infektiologie?
